Botswana to implement pilot HIV/TB program, redesign malaria program

NewsGuard 100/100 Score

Botswana's Health Minister Lesego Motsumi on Monday presented a pilot program to address HIV/tuberculosis coinfection and support health workers who are treating patients with HIV/TB coinfection, Mmegi reports.

Motsumi said the increase in cases of multi-drug resistant and extensively drug-resistant TB in the country could undermine the decline in TB cases over the last five years, adding that increased TB prevention, care and support services are needed for both health workers and patients to slow the spread of the disease. The program will be rolled out in six hospitals and two clinics, Motsumi said. She added that the number of reported TB cases in the country decreased from 470 cases per 100,000 people in 2007 to 623 cases per 100,000 people in 2002.

In addition, Mostumi said the Ministry of Health plans to redesign the country's malaria program and increase malaria control interventions, with the goal of eradicating the disease. She added that the number of unconfirmed malaria cases increased from an average of 3,446 cases in the first five weeks of each year between 2005 and 2008 to 4,933 cases in the same period of 2009 (Gaotlhobogwe, Mmegi, 3/4).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Innovative malaria prodrug targets liver, enhances efficacy while reducing toxicity, preclinical studies show